6.31

9.17% 0.53

After Hours: 6.31

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $6.31, with a volume of 4.72M. It is up +9.17% in the last 24 hours and down -24.97% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$5.78

Open:

$5.8

24h Volume:

4.72M

Relative Volume:

5.04

Market Cap:

$291.70M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-1.9238

EPS:

-3.28

Net Cash Flow:

$-78.56M

1W Performance:

-2.92%

1M Performance:

-24.97%

6M Performance:

-72.09%

1Y Performance:

-66.88%

1-Day Range:

$5.74

$6.37

1-Week Range:

$5.58

$6.77

52-Week Range:

$5.58

$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

201

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	6.31	291.70M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

03:24 AM

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

03:24 AM

Dec 18, 2024

What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga

Dec 18, 2024

Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat

Dec 18, 2024

Dec 17, 2024

Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8% - MarketBeat

Dec 17, 2024

Dec 16, 2024

4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com India

Dec 16, 2024

4DMT Announces Landmark Publication of 4D-150 Preclinical - GlobeNewswire

Dec 16, 2024

4D Molecular's R100 Vector Shows 10X Potency Breakthrough in Landmark Eye Disease Study - StockTitan

Dec 16, 2024

Dec 13, 2024

4D Molecular Therapeutics stock hits 52-week low at $6.69 By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

4D Molecular Therapeutics issues pre-funded warrant to RA Capital - Investing.com

Dec 12, 2024

4D Molecular Therapeutics issues pre-funded warrant to RA Capital By Investing.com - Investing.com Canada

Dec 12, 2024

Dec 07, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 07, 2024

84,322 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by Walleye Capital LLC - MarketBeat

Dec 07, 2024

Dec 06, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - The Eastern Progress Online

Dec 06, 2024

BlackRock, Inc. Expands Stake in 4D Molecular Therapeutics Inc - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal phase - Investing.com India

Dec 05, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Redmile Group LLC - MarketBeat

Dec 05, 2024

Dec 04, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.32 By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 03, 2024

4D Molecular Therapeutics stock hits 52-week low at $7.32 - Investing.com India

Dec 03, 2024

Nov 30, 2024

Healthcare of Ontario Pension Plan Trust Fund Sells 247,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Nov 30, 2024

Braidwell LP Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Nov 30, 2024

Nov 26, 2024